JNJ-67856633
Phase 1Small molecule
Johnson & JohnsonJNJ-67856633 is one of 69 small molecule programs targeting Chronic Lymphocytic Leukemia. It is currently in Phase 1.
2
Indications
4
Total Trials
1
Active Trials
68
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
367 competitors in Chronic Lymphocytic Leukemia
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Venclexta
AbbViePhase 3
Gazyva
RochePhase 3
Calquence
AstraZenecaPhase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Nipent
PfizerPhase 3
Brukinsa
BBeOne Medicines
Phase 3
Adcetris
PfizerPhase 3
Medrol
PfizerPhase 3
Beqalzi
BBeOne Medicines
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Lymphocytic Leukemia2 trials
B-cell NHL1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JNJ-67856633. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company